...
首页> 外文期刊>Central nervous system agents in medicinal chemistry >Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
【24h】

Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review

机译:神经精神疾病中使用α-甲基-对-酪氨酸(AMPT)的挑战和治疗研究:综述

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Alpha-methyl-para-tyrosine (AMPT) temporarily inhibits tyrosine hydroxylase, the rate limiting step in the dopamine biosynthesis cascade. AMPT has been approved for clinical use in phaeochromocytoma in 1979. Recently however, AMPT has been increasingly employed as a pharmacological challenge in acute dopamine depletion studies including neuroimaging studies. The use of this exciting challenge technique allows us to increase our understanding of dopa-minergic neurotransmission in the brain. In addition, there have been clinical reports that AMPT may be useful to treat movement disorders like dystonia, dyskinesia and Huntington's chorea, psychiatric disorders like mania, psychosis, obsessive compulsive disorder and substance abuse as well as behavioral problems in 22qll deletion syndrome. In this review we will discuss the effects of AMPT in challenge studies that have been reported in humans. Furthermore we will review all studies reporting therapeutic effects of AMPT in neuropsychiatric disorders and adverse effects associated with AMPT use reported in both challenge and therapeutic research.
机译:α-甲基-对-酪氨酸(AMPT)暂时抑制酪氨酸羟化酶,这是多巴胺生物合成级联反应中的限速步骤。 1979年,AMPT被批准用于嗜铬细胞瘤的临床应用。然而,最近,AMPT在包括神经影像学研究在内的急性多巴胺耗竭研究中越来越多地被用作药理挑战。这种令人兴奋的挑战技术的使用使我们能够加深对大脑中多巴矿能神经传递的理解。此外,有临床报告表明,AMPT可用于治疗运动障碍,如肌张力障碍,运动障碍和亨廷顿舞蹈病,精神病如躁狂症,精神病,强迫症和药物滥用以及22qll缺失综合征的行为问题。在这篇综述中,我们将讨论AMPT在人类已报道的挑战研究中的作用。此外,我们将审查所有在挑战性和治疗性研究中报告了AMPT在神经精神疾病中的治疗效果以及与AMPT使用相关的不良反应的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号